Preview

Научно-практическая ревматология

Расширенный поиск

Обзор рекомендаций Американской коллегии ревматологов и Американской ассоциации хирургов по периоперационному ведению и антиревматической терапии пациентов с ревматическими заболеваниями перед тотальным эндопротезированием коленных и тазобедренных суставов – 2017

https://doi.org/10.14412/1995-4484-2018-549-555

Полный текст:

Аннотация

В статье приводятся разработанные Американской коллегией ревматологов и Американской ассоциацией хирургов рекомендации по периоперационному лечению больных ревматоидным артритом, анкилозирующим спондилитом, псориатическим артритом, ювенильным идиопатическим артритом и системной красной волчанкой, которым проводится плановое эндопротезирование тазобедренного или коленного сустава. Рассматривается периоперационное применение противоревматической лекарственной терапии, включая базисные противовоспалительные препараты, генно-инженерные биологические препараты, тофацитиниб и глюкокортикоиды. Все рекомендации являются условными и основаны на результатах ретроспективных клинических исследований, которые следует учитывать, принимая решения при выборе периоперационной антиревматической терапии.

Об авторах

В. Н. Амирджанова
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия

Москва, Россия 115522, Москва, Каширское шоссе, 34А



А. Е. Каратеев
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Москва, Россия 115522, Москва, Каширское шоссе, 34А


Е. Ю. Погожева
ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»
Россия
Москва, Россия 115522, Москва, Каширское шоссе, 34А


Список литературы

1. Goodman SM, Springer B, Guyatt G, et al. 2017 American College of Rheumatology/American Association of Hip and Knee Surgeons Guideline for the Perioperative Management of Antirheumatic Medication in Patients With Rheumatic Diseases Undergoing Elective Total Hip or Total Knee Arthroplasty. Arthritis Rheum. 2017;69(8):1538-51. doi: 10.1002/art.40149

2. Strand V, Singh JA. Improved health-related quality of life with effective disease-modifying antirheumatic drugs: evidencefrom randomized controlled trials. Am J Manag Care. 2008;14:234-54.

3. Ravi B, Croxford R, Reichmann WM, et al. The changing demographics of total joint arthroplasty recipients in the United States and Ontario from 2001 to 2007. Best Pract Res Clin Rheumatol. 2012;26:637-47. doi: 10.1016/j.berh.2012.07.014

4. Mertelsmann-Voss C, Lyman S, Pan TJ, et al. Arthroplasty rates are increased among US patients with systemic lupus erythematosus: 1991-2005. J Rheumatol. 2014;41:867-74. doi: 10.3899/jrheum.130617

5. Mertelsmann-Voss C, Lyman S, Pan TJ, et al. US trends in rates of arthroplasty for inflammatory arthritis including rheumatoid arthritis, juvenile idiopathic arthritis, and spondyloarthritis. Arthritis Rheum. 2014;66:1432-9. doi: 10.1002/art.38384

6. Nikiphorou E, Carpenter L, Morris S, et al. Hand and foot surgery rates in rheumatoid arthritis have declined from 1986 to 2011, but large-joint replacement rates remain unchanged: results from two UK inception cohorts. Arthritis Rheum. 2014;66:1081-9. doi: 10.1002/art.38344

7. Sokka T, Kautiainen H, Hannonen P. Stable occurrence of knee and hip total joint replacement in Central Finland between 1986 and 2003: an indication of improved longterm outcomes of rheumatoid arthritis. Ann Rheum Dis. 2007;66:341-4. doi: 10.1136/ard.2006.057067

8. Ravi B, Croxford R, Hollands S, et al. Increased risk of complications following total joint arthroplasty in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:254-63. doi: 10.1002/art.38231

9. Lin JA, Liao CC, Lee YJ, et al. Adverse outcomes after major surgery in patients with systemic lupus erythematosus: a nationwide population-based study. Ann Rheum Dis. 2014;73:1646-51. doi: 10.1136/annrheumdis-2012-202758

10. Singh JA, Inacio MC, Namba RS, Paxton EW. Rheumatoid arthritis is associated with higher ninety-day hospital readmission rates compared to osteoarthritis after hip or knee arthroplasty: a cohort study. Arthritis Care Res (Hoboken). 2015;67:718-24. doi: 10.1002/acr.22497

11. Roberts JE, Mandl LA, Su EP, et al. Patients with systemic lupus erythematosus have increased risk of short-term adverse events after total hip arthroplasty. J Rheumatol. 2016;43:1498-502. doi: 10.3899/jrheum.151373

12. Насонов ЕЛ, Мазуров ВИ, Каратеев ДЕ и др. Проект рекомендаций по лечению ревматоидного артрита Общероссийской общественной организации «Ассоциация ревматологов России» – 2014 (часть 1). Научно-практическая ревматология. 2014;52(5):477-95 [Nasonov EL, Mazurov VI, Karateev DE, et al. Spondyloarthritis: Evolution of a concept. Project: recommendations on treatment of rheumatoid arthritis developed by All-Russian Public organization «Association of Rheumatologists of Russia» – 2014 (part 1). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(5):477-94 (In Russ.)]. doi: 10.14412/1995-4484-2014-477-494

13. Goodman SM, Ramsden-Stein DN, Huang WT, et al. Patients with rheumatoid arthritis are more likely to have pain and poor function after total hip replacements than patients with osteoarthritis. J Rheumatol. 2014;41:1774-80. doi: 10.3899/jrheum.140011

14. Goodman SM, Johnson B, Zhang M, et al. Patients with rheumatoid arthritis have similar excellent outcomes after total knee replacement compared with patients with osteoarthritis. J Rheumatol. 2016;43:46-53. doi: 10.3899/jrheum.150525

15. LoVerde ZJ, Mandl LA, Johnson BK, et al. Rheumatoid arthritis does not increase risk of short-term adverse events after total knee arthroplasty: a retrospective case-control study. J Rheumatol. 2015;42:1123-30. doi: 10.3899/jrheum.141251

16. Johnson BK, Goodman SM, Alexiades MM, et al. Patterns and associated risk of perioperative use of anti-tumor necrosis factor in patients with rheumatoid arthritis undergoing total knee replacement. J Rheumatol. 2013;40:617-23. doi: 10.3899/jrheum.121171

17. Berbari EF, Osmon DR, Lahr B, et al. The Mayo prosthetic joint infection risk score: implication for surgical site infection reporting and risk stratification. Infect Control Hosp Epidemiol. 2012;33:774-81. doi: 10.1086/666641

18. Bongartz T, Halligan CS, Osmon DR, et al. Incidence and risk factors of prosthetic joint infection after total hip or knee replacement in patients with rheumatoid arthritis. Arthritis Rheum. 2008;59:1713-20. doi: 10.1002/art.24060

19. Goodman SM, Menon I, Christos PJ, et al. Management of perioperative tumour necrosis factor a inhibitors in rheumatoid arthritis patients undergoing arthroplasty: a systematic review and metaanalysis. Rheumatology (Oxford). 2016;55:573-82.

20. Au K, Reed G, Curtis JR, et al. High disease activity is associated with an increased risk of infection in patients with rheumatoid arthritis. Ann Rheum Dis. 2011;70:785-91.doi: 10.1136/ard.2010.128637

21. Doran MF, Crowson CS, Pond GR, et al. Predictors of infection in rheumatoid arthritis. Arthritis Rheum. 2002;46:2294-300. doi: 10.1002/art.10529

22. Kurtz SM, Lau E, Watson H, et al. Economic burden of periprosthetic joint infection in the United States. J Arthroplasty. 2012;Suppl 27:61-5. doi: 10.1016/j.arth.2012.02.022

23. Centers for Disease Control and Prevention. General recommendations on immunization: recommendations of the Advisory Committee on Immunization Practices. MMWR. 2011;60:22-3.

24. Salmon JE, Roman MJ. Subclinical atherosclerosis in rheumatoid arthritis and systemic lupus erythematosus. Am J Med. 2008;Suppl 1:S3-8. doi: 10.1016/j.amjmed.2008.06.010

25. Периоперационное ведение пациентов с ревматоидным артритом, нуждающихся в эндопротезировании крупных суставов нижних конечностей. В кн.: Насонов ЕЛ, редактор. Российские клинические рекомендации «Ревматология». Москва: ГЭОТАР-Медиа; 2017. С. 360-70 [Perioperative management of patients with rheumatoid arthritis who need endoprosthetics of large joints of lower extremities. In: Nasonov EL, editor. Rossiyskie klinicheskie rekomendatsii «Revmatologiya» [Russian Clinical Recommendations «Rheumatology»]. Moscow: GEOTAR-Media; 2017. P. 360-70 (In Russ.)].

26. Амирджанова ВН, Макаров МА, Бялик ЕИ и др. Периоперационное ведение больных ревматоидным артритом. Научно-практическая ревматология. 2014;52(4):366-76 [Amirdzhanova VN, Makarov MA, Byalik EI, et al. Perioperative

27. management of patients with rheumatoid arthritis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(4):366-75 (In Russ.)]. doi: 10.14412/1995-4484-2014-366-375

28. American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, et al.

29. ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery. J Am Coll Cardiol. 2009;54:e13-118. doi: 10.1016/j.jacc.2009.07.010

30. Fleisher LA, Beckman JA, Brown KA, et al. 2009 ACCF/AHA focused update on perioperative b blockade incorporated into the ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. Circulation. 2009;120:e169-276. doi: 10.1161/CIRCULATIONAHA.109.192690

31. Falck-Ytter Y, Francis CW, Johanson NA, et al. Prevention of VTE in orthopedic surgery patients: antithrombotic therapy and prevention of thrombosis, 9th ed. American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2012;141 Suppl 2:e278S-325S.

32. Jacobs JJ, Mont MA, Bozic KJ, et al. American Academy of Orthopaedic Surgeons clinical practice guideline on: preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty. J Bone Joint Surg Am. 2012;94:746-7. doi: 10.2106/JBJS.9408.EBO746

33. Савенкова НА. Амирджанова ВН, Макаров СА и др. Отменять ли базисную терапию больным ревматоидным артритом перед эндопротезированием суставов? Научно-практическая ревматология. 2011;49(5):46-50 [Savenkova NA,

34. Amirdzhanova VN, Makarov SA, et al. Should disease-modifying therapy be stopped in patients with rheumatoid arthritis before endoprosthetic joint replacement? Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2011;49(5):46-50 (In Russ.)]. doi: 10.14412/1995-4484-2011-1460

35. Strand V, Ahadieh S, French J, et al. Systematic review and metaanalysis of serious infections with tofacitinib and biologic diseasemodifying antirheumatic drug treatment in rheumatoid arthritis clinical trials. Arthritis Res Ther. 2015;17:362. doi: 10.1186/s13075-015-0880-2

36. Singh JA, Cameron C, Noorbaloochi S, et al. Risk of serious infection in biological treatment of patients with rheumatoid arthritis: a systematic review and meta-analysis. Lancet. 2015;386:258-65. doi: 10.1016/S0140-6736(14)61704-9

37. Maxwell LJ, Zochling J, Boonen A, et al. TNF-a inhibitors for ankylosing spondylitis. Cochrane Database Syst Rev. 2015;4:CD005468.

38. Ito H, Kojima M, Nishida K, et al. Postoperative complications in patients with rheumatoid arthritis using a biological agent: a systematic review and meta-analysis. Mod Rheumatol. 2015;25:672-8. doi: 10.3109/14397595.2015.1014302

39. Lopez-Olivo MA, Amezaga Urruela M, McGahan L, et al. Rituximab for rheumatoid arthritis. Cochrane Database Syst Rev. 2015;1:CD007356.

40. Ruiz Garcia V, Jobanputra P, Burls A, et al. Certolizumab pegol (CDP870) for rheumatoid arthritis in adults. Cochrane Database Syst Rev. 2014;9:CD007649.

41. Song GG, Bae SC, Lee YH. Efficacy and safety of tofacitinib for active rheumatoid arthritis with an inadequate response to methotrexate or disease-modifying antirheumatic drugs: a metaanalysis of randomized controlled trials. Korean J Intern Med. 2014;29:656-63. doi: 10.3904/kjim.2014.29.5.656

42. Cohen S, Radominski SC, Gomez-Reino JJ, et al. Analysis of infections and all-cause mortality in phase II, phase III, and longterm extension studies of tofacitinib in patients with rheumatoid arthritis. Arthritis Rheum. 2014;66:2924-37. doi: 10.1002/art.38779

43. Michaud TL, Rho YH, Shamliyan T, et al. The comparative safety of tumor necrosis factor inhibitors in rheumatoid arthritis: a metaanalysis update of 44 trials. Am J Med. 2014;127:1208-32. doi: 10.1016/j.amjmed.2014.06.012

44. Borba HH, Wiens A, de Souza TT, et al. Efficacy and safety of biologic therapies for systemic lupus erythematosus treatment: systematic review and meta-analysis. BioDrugs 2014;28:211-28. doi: 10.1007/s40259-013-0074-x

45. He Y, Wong AY, Chan EW, et al. Efficacy and safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. BMC Musculoskelet Disord. 2013;14:298. doi: 10.1186/1471-2474-14-298

46. Lethaby A, Lopez-Olivo MA, Maxwell L, et al. Etanercept for the treatment of rheumatoid arthritis. Cochrane Database Syst Rev. 2013;5:CD004525.

47. Machado MA, Barbosa MM, Almeida AM, et al. Treatment of ankylosing spondylitis with TNF blockers: a meta-analysis. Rheumatol Int. 2013;33:2199-213. doi: 10.1007/s00296-013-2772-6

48. Li ZH, Zhang Y, Wang J, Shi ZJ. Etanercept in the treatment of ankylosing spondylitis: a meta-analysis of randomized, doubleblind, placebo-controlled clinical trials, and the comparison of the Caucasian and Chinese population. Eur J Orthop Surg Traumatol. 2013;23:497-506. doi: 10.1007/s00590-012-1035-7

49. Schoels MM, van der Heijde D, Breedveld FC, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and metaanalysis informing a consensus statement. Ann Rheum Dis. 2013;72:583-9. doi: 10.1136/annrheumdis-2012-202470

50. Lan L, Han F, Chen JH. Efficacy and safety of rituximab therapy for systemic lupus erythematosus: a systematic review and metaanalysis. J Zhejiang Univ Sci B. 2012;13:731-44. doi: 10.1631/jzus.B1200057

51. Dommasch ED, Abuabara K, Shin DB, et al. The risk of infection and malignancy with tumor necrosis factor antagonists in adults with psoriatic disease: a systematic review and meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:1035- 50. doi: 10.1016/j.jaad.2010.09.734

52. Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford). 2011;50:552-62. doi: 10.1093/rheumatology/keq343

53. Lee YH, Bae SC, Song GG. The efficacy and safety of rituximab for the treatment of active rheumatoid arthritis: a systematic review and meta-analysis of randomized controlled trials. Rheumatol Int. 2011;31:1493-9. doi: 10.1007/s00296-010-1526-y

54. Katikireddi VS, Whittle SL, Hill CL. Tumour necrosis factor inhibitors and risk of serious infection in rheumatoid arthritis. Int J Rheum Dis. 2010;13:12-26. doi: 10.1111/j.1756-185X.2009.01457.x

55. Wiens A, Venson R, Correr CJ, et al. Meta-analysis of the efficacy and safety of adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. Pharmacotherapy. 2010;30:339-53. doi: 10.1592/phco.30.4.339

56. Storage SS, Agrawal H, Furst DE. Description of the efficacy and safety of three new biologics in the treatment of rheumatoid arthritis. Korean J Intern Med. 2010;25:1-17. doi: 10.3904/kjim.2010.25.1.1

57. An MM, Zou Z, Shen H, et al. The addition of tocilizumab to DMARD therapy for rheumatoid arthritis: a meta-analysis of randomized controlled trials. Eur J Clin Pharmacol. 2010;66:49-59. doi: 10.1007/s00228-009-0754-0

58. Wiens A, Correr CJ, Pontarolo R, et al. A systematic review and meta-analysis of the efficacy and safety of etanercept for treating rheumatoid arthritis. Scand J Immunol. 2009;70:337-44. doi: 10.1111/j.1365-3083.2009.02296.x

59. Fouque-Aubert A, Jette-Paulin L, Combescure C, et al. Serious infections in patients with ankylosing spondylitis with and without TNF blockers: a systematic review and meta-analysis of randomised placebocontrolled trials. Ann Rheum Dis. 2010;69:1756-61. doi: 10.1136/ard.2008.098822

60. Leombruno JP, Einarson TR, Keystone EC. The safety of antitumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events. Ann Rheum Dis. 2009;68:1136-45. doi: 10.1136/ard.2008.091025

61. Alonso-Ruiz A, Pijoan JI, Ansuategui E, et al. Tumor necrosis factor a drugs in rheumatoid arthritis: systematic review and metaanalysis of efficacy and safety. BMC Musculoskelet Disord. 2008;9:52. doi: 10.1186/1471-2474-9-52

62. Saad AA, Symmons DP, Noyce PR, Ashcroft DM. Risks and benefits of tumor necrosis factor-a inhibitors in the management of psoriatic arthritis: systematic review and metaanalysis of randomized controlled trials. J Rheumatol. 2008;35:883-90.

63. Gartlehner G, Hansen RA, Jonas BL, et al. The comparative efficacy and safety of biologics for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol. 2006;33:2398-408.

64. Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA. 2006;295:2275-85. doi: 10.1001/jama.295.19.2275

65. Fleischmann R, Baumgartner SW, Weisman MH, et al. Long term safety of etanercept in elderly subjects with rheumatic diseases. Ann Rheum Dis. 2006;65:379-84. doi: 10.1136/ard.2005.035287

66. Capogrosso Sansone A, Mantarro S, Tuccori M, et al. Safety profile of certolizumab pegol in patients with immune-mediated inflammatory diseases: a systematic review and meta-analysis. Drug Safety. 2015;38:869-88. doi: 10.1007/s40264-015-0336-2

67. Tarp S, Furst DE, Luta G, et al. Risk of serious adverse effects associated with different biological and targeted synthetic diseasemodifying anti-rheumatic drugs in patients with rheumatoid arthritis: a systematic review and meta-analysis of randomised trials [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:176-7.

68. doi: 10.1136/annrheumdis-2015-eular.3288

69. De la Forest M, Brugneaux J, Utard G, Salliot C. Safety of anti-TNFs in RA patients in real life: results from a systematic literature review and meta-analyses from biologic registers [abstract]. Ann Rheum Dis. 2015;74 Suppl 2:702. doi: 10.1136/annrheumdis-2015-eular.2781

70. Hochberg M, Janssen K, Broglio K, et al. Comparison of abatacept and other biologic DMARDs for the treatment of rheumatoid arthritis patients: a systematic literature review and network metaanalysis [abstract]. Ann Rheum Dis. 2014;73 Suppl 2:676. doi: 10.1136/annrheumdis-2014-eular.5331

71. Tarp S, Tarp U, Andersen LS, et al. Serious adverse events associated with using biological agents to treat rheumatic diseases: network meta-analysis from a national guideline panel [abstract]. Arthritis Rheum. 2013;65 Suppl:S997-8.

72. He Y, Wong A, Chan E, et al. Safety of tofacitinib in the treatment of rheumatoid arthritis: a systematic review and meta-analysis. Drug Safety. 2013;36:852-3.

73. Singh JA, Wells G, Christensen R, et al. Risk of cancer, serious lung infections and death with biologics: a systematic review and network meta-analysis of randomized controlled trials (RCTs) [abstract]. Ann Rheum Dis. 2013;72:A74. doi: 10.1136/annrheumdis-2013-eular.276

74. Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials. J Pharmacokinetics Pharmacodynamics. 2013;40:S93-4.

75. Lin T, Shamliyan T, Choi H, et al. The safety of anti-TNF biologic agents in rheumatoid arthritis: a metaanalysis of 35 RCTs [abstract]. Arthritis Rheum. 2012;64 Suppl:S1854.

76. Venson R, Wiens A, Correr CJ, Pontarolo R. Efficacy, safety and tolerability of using abatacept for the treatment of rheumatoid arthritis. Brazil J Pharm Sci. 2012;48:781-91. doi: 10.1590/S1984-82502012000400022

77. Cormier H, Barnetche T, Schaeverbeke T. The risk of serious infection with and without anti-TNF therapy in rheumatoid arthritis and ankylosing spondylitis: a metaanalysis [abstract]. Arthritis Rheum. 2011;63 Suppl:S878.

78. Dommasch E, Troxel A, Shin D, et al. The safety of tumor necrosis factor antagonists in patients with psoriatic disease: a systematic review and metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2011;64:AB8. doi: 10.1016/j.jaad.2010.09.734

79. Rieder S, Thompson A, Pope J. Anti-TNF therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials. J Rheumatol. 2010;37:1343.

80. Powers J, Martin R. Incidence of serious infectious events with methotrexate treatment: metaanalysis of randomized controlled trials. J Am Acad Dermatol. 2010;62:AB4.

81. Volkmann ER, Agrawal H, Maranian P, Furst DE. Rituximab for rheumatoid arthritis: a meta-analysis and systematic review. Clin Med. 2010;2:749-60.

82. Kaine JL. Abatacept for the treatment of rheumatoid arthritis: a review. Curr Ther Res. 2007;68:379-99. doi: 10.1016/j.curtheres. 2007.12.001

83. Nestorov I. Clinical pharmacokinetics of TNF antagonists: how do they differ? Semin Arthritis Rheum. 2005;34 Suppl 1:12-8. doi: 10.1016/j.semarthrit.2005.01.004

84. Jinesh S. Pharmaceutical aspects of anti-inflammatory TNFblocking drugs. Inflammopharmacology. 2015;23:71-7. doi: 10.1007/s10787-015-0229-0

85. Weisman MH, Moreland LW, Furst DE, et al. Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human antitumor necrosis factor-a monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study. Clin Ther. 2003;25:1700-21. doi: 10.1016/S0149-2918(03)80164-9

86. Breedveld F, Agarwal S, Yin M, et al. Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response. J Clin Pharmacol. 2007;47:1119-28. doi: 10.1177/0091270007305297

87. Погожева ЕЮ, Амирджанова ВН, Макаров СА, Насонов ЕЛ. Осложнения после эндопротезирования суставов у пациентов, получающих генно-нженерные биологические препараты. Научно-практическая ревматология. 2012;50(3):43-8 [Pogozheva EYu, Amirdzhanova VN, Makarov SA, Nasonov EL. Complications after endoprosthetic joint replacement in patients receiving genetically engineered biological agents. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(3):43-8 (In Russ.)]. doi: 10.14412/1995-4484-2012-708

88. Tarp S, Furst DE, Maarten B, et al. Risk of serious adverse effects of biological and targeted drugs in patients with rheumatoid arthritis: a systematic review meta-analysis. Rheumatology (Oxford). 2017;56:417-25.

89. Ramos-Casals M, Soto MJ, Cuadrado MJ, Khamashta MA. Rituximab in systemic lupus erythematosus: a systematic review of off-label use in 188 cases. Lupus. 2009;18:767-76. doi: 10.1177/0961203309106174

90. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: a systematic review. Clin Rheumatol. 2010;29:707-16. doi: 10.1007/s10067-010-1387-5

91. Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebocontrolled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus. Arthritis Rheum. 2011;63:3918-30. doi: 10.1002/art.30613

92. Ahadieh S, Checchio T, Tensfeldt T, et al. Meta-analysis of malignancies, serious infections, and serious adverse events with tofacitinib or biologic treatment in rheumatoid arthritis clinical trials [abstract]. Arthritis Rheum. 2012;64(10 Suppl):S726.

93. Boyle DL, Soma K, Hodge J, et al. The JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signaling in rheumatoid arthritis. Ann Rheum Dis. 2015;74:1311-6. doi: 10.1136/annrheumdis-2014-206028

94. Marik PE, Varon J. Requirement of perioperative stress doses of corticosteroids: a systematic review of the literature. Arch Surg. 2008;143:1222-6. doi: 10.1001/archsurg.143.12.1222

95. Harpaz R, Ortega-Sanchez I, Seward J. Prevention of herpes zoster: recommendation of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2008;57:1-30.

96. Somayaji R, Barnabe C, Martin L. Risk factors for infection following total joint arthroplasty in rheumatoid arthritis. Open Rheumatol J. 2013;7:119-24. doi: 10.2174/1874312920131210005


Для цитирования:


Амирджанова В.Н., Каратеев А.Е., Погожева Е.Ю. Обзор рекомендаций Американской коллегии ревматологов и Американской ассоциации хирургов по периоперационному ведению и антиревматической терапии пациентов с ревматическими заболеваниями перед тотальным эндопротезированием коленных и тазобедренных суставов – 2017. Научно-практическая ревматология. 2018;56(5):549-555. https://doi.org/10.14412/1995-4484-2018-549-555

For citation:


Amirdzhanova V.N., Karateev A.E., Pogozheva E.Y. REVIEW OF THE 2017 AMERICAN COLLEGE OF RHEUMATOLOGY/AMERICAN ASSOCIATION OF HIP AND KNEE SURGEONS GUIDELINES FOR THE PERIOPERATIVE MANAGEMENT AND ANTIRHEUMATIC THERAPY OF PATIENTS WITH RHEUMATIC DISEASES BEFORE TOTAL KNEE AND HIP ARTHROPLASTY. Rheumatology Science and Practice. 2018;56(5):549-555. (In Russ.) https://doi.org/10.14412/1995-4484-2018-549-555

Просмотров: 358


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)